First-line bevacizumab (BEV) plus chemotherapy for hormone receptor-positive metastatic breast cancer (mBC): Subgroup analysis of the open-label non-inferiority TURANDOT phase III trial.

被引：1
|
作者：
Kahan, Zsuzsanna [1 ]
Petruzelka, Lubos [2 ]
Eniu, Alexandru [3 ]
Anghel, Rodica [4 ]
Koynov, Krassimir [5 ]
Vrbanec, Damir [6 ]
Lang, Istvan [7 ]
Ahlers, Silke [8 ]
Brodowicz, Thomas [9 ,10 ]
Zielinski, Christoph [9 ,10 ]
机构：
[1] Univ Szeged, Szeged, Hungary
[2] Charles Univ Prague, Prague, Czech Republic
[3] Inst Canc Res, Cluj Napoca, Romania
[4] Univ Med & Pharm Bucharest, Bucharest, Romania
[5] Univ Hosp, Sofia, Bulgaria
[6] Univ Hosp Rebro, Zagreb, Croatia
[7] Natl Inst Oncol, Budapest, Hungary
[8] IST GmbH, Mannheim, Germany
[9] Med Univ Vienna, Vienna, Austria
[10] CECOG, Vienna, Austria
来源：
CANCER RESEARCH | 2013年 / 73卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2013-LB-177
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB177
引用
收藏
页数：2
相关论文
共 50 条
  • [21] First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial
    Rimawi, Mothaffar
    Ferrero, Jean-Marc
    de la Haba-Rodriguez, Juan
    Poole, Christopher
    De Placido, Sabino
    Osborne, C. Kent
    Hegg, Roberto
    Easton, Valerie
    Wohlfarth, Christine
    Arpino, Grazia
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (28) : 2826 - +
  • [22] Maintenance hormone therapy with letrozole after first-line chemotherapy in postmenopausal patients with hormone receptor-positive metastatic breast cancer
    Borrego, M. Ruiz
    De la Haba, J.
    Morales, S.
    Ramos, M.
    Velasco, A.
    Mendez, M.
    Carabantes, F.
    Barnadas, A.
    Garcia, M.
    Moreno, J. A.
    EJC SUPPLEMENTS, 2005, 3 (02): : 117 - 117
  • [23] FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trial
    Loupakis, Fotios
    Cremolini, Chiara
    Masi, Gianluca
    Lonardi, Sara
    Zagonel, Vittorina
    Trenta, Patrizia
    Tomasello, Gianluca
    Ronzoni, Monica
    Ciuffreda, Libero
    Zaniboni, Alberto
    Tonini, Giuseppe
    Buonadonna, Angela
    Valsuani, Chiara
    Chiara, Silvana
    Carlomagno, Chiara
    Boni, Corrado
    Marcucci, Lorenzo
    Boni, Luca
    Falcone, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [24] Maintenance hormone therapy with letrozole after first-line chemotherapy in postmenopausal patients with hormone receptor-positive metastatic breast cancer
    Ruiz, Manuel
    De la Haba, Juan
    Morales, Serafin
    Ramos, Manuel
    Velasco, Amlia
    Mendez, Miguel
    Carabantes, Francisco
    Barnadas, Agusti
    Garcia, Maria
    Moreno, Jose A.
    ANNALS OF ONCOLOGY, 2004, 15 : 35 - 35
  • [25] Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer
    Hans-Joachim Lück
    Kristina Lübbe
    Mattea Reinisch
    Nicolai Maass
    Gabriele Feisel-Schwickardi
    Oliver Tomé
    Wolfgang Janni
    Mustafa Aydogdu
    Tanja Neunhöffer
    Angelika Ober
    Bahriye Aktas
    Tjoung-Won Park-Simon
    Claudia Schumacher
    Heinz-Gert Höffkes
    Thomas Illmer
    Harald Wagner
    Keyur Mehta
    Gunter von Minckwitz
    Valentina Nekljudova
    Sibylle Loibl
    Breast Cancer Research and Treatment, 2015, 149 : 141 - 149
  • [26] Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer
    Lueck, Hans-Joachim
    Luebbe, Kristina
    Reinisch, Mattea
    Maass, Nicolai
    Feisel-Schwickardi, Gabriele
    Tome, Oliver
    Janni, Wolfgang
    Aydogdu, Mustafa
    Neunhoeffer, Tanja
    Ober, Angelika
    Aktas, Bahriye
    Park-Simon, Tjoung-Won
    Schumacher, Claudia
    Hoeffkes, Heinz-Gert
    Illmer, Thomas
    Wagner, Harald
    Mehta, Keyur
    von Minckwitz, Gunter
    Nekljudova, Valentina
    Loibl, Sibylle
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 149 (01) : 141 - 149
  • [27] Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line chemotherapy (CT) for HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC): Preliminary safety data from the CECOG phase III TURANDOT trial.
    Lang, I.
    Inbar, M. J.
    Greil, R.
    Steger, G. G.
    Beslija, S.
    Kahan, Z.
    Eniu, A. E.
    Zvirbule, Z.
    Sirbu, D. E.
    Zielinski, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [28] FAMILY: A randomized, multicenter, open-label, phase III trial of fulvestrant versus capecitabine as maintenance therapy after first-line combination chemotherapy in patients with hormone receptor-positive, human epidermal growth factor receptor-2 negative metastatic breast cancer
    Yao, H.
    Wu, W.
    Ding, L.
    Yu, Y.
    Wang, Y.
    Zeng, Y.
    Zhao, J.
    Li, Q.
    CANCER RESEARCH, 2019, 79 (04)
  • [29] Lapatinib plus Letrozole as First-Line Therapy for HER-2+ Hormone Receptor-Positive Metastatic Breast Cancer
    Schwarzberg, Lee S.
    Franco, Sandra X.
    Florance, Allison
    O'Rourke, Lisa
    Maltzman, Julie
    Johnston, Stephen
    ONCOLOGIST, 2010, 15 (02): : 122 - 129
  • [30] Maintenance strategy with fluoropyrimidines (FP) plus Bevacizumab (Bev), Bev alone, or no treatment, following a standard combination of FP, oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC): A phase III non-inferiority trial (AIO KRK 0207).
    Arnold, Dirk
    Graeven, Ullrich
    Lerchenmuller, Christian A.
    Killing, Brigitta
    Depenbusch, Reinhard
    Steffens, Claus-Christoph
    Al-Batran, Salah-Eddin
    Lange, Thoralf
    Dietrich, Georg
    Stoehimacher, Jan
    Tannapfel, Andrea
    Schmoll, Hans-Joachim
    Reinacher-Schick, Anke
    Hegewisch-Becker, Susanna
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345